 Sirolimus
"Sirolimus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.
| Descriptor ID |
D020123
|
| MeSH Number(s) |
D02.540.505.760
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sirolimus".
Below are MeSH descriptors whose meaning is more specific than "Sirolimus".
This graph shows the total number of publications written about "Sirolimus" by people in this website by year, and whether "Sirolimus" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 0 | 2 | 2 | | 1993 | 0 | 1 | 1 | | 1996 | 0 | 3 | 3 | | 1997 | 0 | 1 | 1 | | 1998 | 1 | 1 | 2 | | 1999 | 4 | 1 | 5 | | 2000 | 6 | 1 | 7 | | 2001 | 4 | 2 | 6 | | 2002 | 1 | 0 | 1 | | 2003 | 5 | 2 | 7 | | 2004 | 2 | 4 | 6 | | 2005 | 3 | 3 | 6 | | 2006 | 5 | 2 | 7 | | 2007 | 6 | 3 | 9 | | 2008 | 6 | 4 | 10 | | 2009 | 6 | 3 | 9 | | 2010 | 13 | 4 | 17 | | 2011 | 7 | 6 | 13 | | 2012 | 5 | 2 | 7 | | 2013 | 9 | 7 | 16 | | 2014 | 7 | 7 | 14 | | 2015 | 2 | 2 | 4 | | 2016 | 8 | 4 | 12 | | 2017 | 3 | 0 | 3 | | 2018 | 1 | 2 | 3 | | 2019 | 4 | 1 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Sirolimus" by people in Profiles.
-
Shokati T, Hartmann M, Davari B, Klawitter J, Klawitter J, Christians U. Temsirolimus metabolic pathways revisited. Xenobiotica. 2020 Jun; 50(6):640-653.
-
Sandmaier BM, Kornblit B, Storer BE, Olesen G, Maris MB, Langston AA, Gutman JA, Petersen SL, Chauncey TR, Bethge WA, Pulsipher MA, Woolfrey AE, Mielcarek M, Martin PJ, Appelbaum FR, Flowers MED, Maloney DG, Storb R. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. Lancet Haematol. 2019 Aug; 6(8):e409-e418.
-
Holditch SJ, Brown CN, Atwood DJ, Lombardi AM, Nguyen KN, Toll HW, Hopp K, Edelstein CL. A study of sirolimus and mTOR kinase inhibitor in a hypomorphic Pkd1 mouse model of autosomal dominant polycystic kidney disease. Am J Physiol Renal Physiol. 2019 07 01; 317(1):F187-F196.
-
Gupta N, Lee HS, Young LR, Strange C, Moss J, Singer LG, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP, Goldberg HJ, Downey GP, Taveira-DaSilva AM, Krischer JP, Setchell K, Trapnell BC, Inoue Y, McCormack FX. Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis. Eur Respir J. 2019 04; 53(4).
-
Preston MA, Finseth LT, Bourne JN, Macklin WB. A novel myelin protein zero transgenic zebrafish designed for rapid readout of in vivo myelination. Glia. 2019 04; 67(4):650-667.
-
Plenter RJ, Grazia TJ, Coulombe MG, Nelsen MK, Lin CM, Scott Beard K, Kupfer TM, Zamora MR, Gill RG, Pietra BA. Anti-LFA-1 induces CD8 T-cell dependent allograft tolerance and augments suppressor phenotype CD8 cells. Cell Immunol. 2018 10; 332:101-110.
-
Roberti SL, Higa R, White V, Powell TL, Jansson T, Jawerbaum A. Critical role of mTOR, PPAR? and PPARd signaling in regulating early pregnancy decidual function, embryo viability and feto-placental growth. Mol Hum Reprod. 2018 06 01; 24(6):327-340.
-
Davis S, Gralla J, Chan L, Wiseman A, Edelstein CL. Effect of Sirolimus on Native Total Kidney Volume After Transplantation in Patients with Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Pilot Study. Transplant Proc. 2018 Jun; 50(5):1243-1248.
-
Heble A, Everitt MD, Gralla J, Miyamoto SD, Lahart M, Eshelman J. Safety of mTOR inhibitor continuation in pediatric heart transplant recipients undergoing surgical procedures. Pediatr Transplant. 2018 02; 22(1).
-
Siroky BJ, Towbin AJ, Trout AT, Schäfer H, Thamann AR, Agricola KD, Tudor C, Capal J, Dixon BP, Krueger DA, Franz DN. Improvement in Renal Cystic Disease of Tuberous Sclerosis Complex After Treatment with Mammalian Target of Rapamycin Inhibitor. J Pediatr. 2017 08; 187:318-322.e2.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|